The Oklahoma Eagle
Now Reading
Which COVID-19 Vaccine Is Better And More Effective? Pfizer, Moderna Or AstraZeneca
The Oklahoma Eagle
The Oklahoma Eagle
  • Follow
John Neal, All-Black Towns, Black Towns, Oklahoma Black Towns, Historic Black Towns, Gary Lee, M. David Goodwin, James Goodwin, Ross Johnson, Sam Levrault, Kimberly Marsh, African American News, Black News, African American Newspaper, Black Owned Newspaper, The Oklahoma Eagle, The Eagle, Black Wall Street, Tulsa Race Massacre, 1921 Tulsa Race Massacre
John Neal, All-Black Towns, Black Towns, Oklahoma Black Towns, Historic Black Towns, Gary Lee, M. David Goodwin, James Goodwin, Ross Johnson, Sam Levrault, Kimberly Marsh, African American News, Black News, African American Newspaper, Black Owned Newspaper, The Oklahoma Eagle, The Eagle, Black Wall Street, Tulsa Race Massacre, 1921 Tulsa Race Massacre

Which COVID-19 Vaccine Is Better And More Effective? Pfizer, Moderna Or AstraZeneca

February 24, 2021

www.ibtimes.com

By Danielle Ong

 

KEY POINTS

  • The FDA has approved two COVID-19 vaccines for use in the U.S.
  • The Pfizer-BioNTech COVID-19 vaccine has a 95% efficacy rate
  • Moderna’s vaccine offers 94% protection against the virus
  • AstraZeneca has been approved for use in the U.K. with 60% effectivity

[The article has been updated to clarify that the COVID-19 vaccine from AstraZeneca has not yet received approval from the U.S. FDA as erroneously stated in an earlier version.]

Coronavirus vaccines are the world’s biggest hope in getting ourselves out of the deadly pandemic that has forced businesses to close, airline flights to remain on the ground, and people to hunker down in order to avoid various degrees of illness.

See Also
Coping With Grief During The Holidays

The U.S. Food and Drug Administration has approved two COVID-19 vaccines for use in this country: one from Moderna, another from Pfizer-BioNTech. A third vaccine, from AstraZeneca-Oxford, has been approved for use in the U.K., but not in the U.S.

 

For the entire article go to: www.ibtimes.com

Scroll To Top